August 2018 Vol 11, Special Issue

Ivosidenib is a potent oral inhibitor of the IDH1 mutation. In a new study presented at ASCO 2018, ivosidenib achieved durable remissions and molecular remissions in some patients with advanced relapsed or refractory acute myeloid leukemia (AML) and IDH1 mutation. In this phase 1 clinical trial, approximately 33% of the patients who received this drug became transfusion-independent. At a dose of 500 mg daily, ivosidenib has been associated with a low frequency of grade ≥3 treatment-related adverse events.
The investigational LOXO-292, a potent and highly selective RET kinase inhibitor, has demonstrated robust and durable antitumor activity against RET-activating fusions and mutations.
The drug affordability rating in the National Comprehensive Cancer Network (NCCN) Evidence Blocks are inconsistent with real-world total episode of care costs, according to Scott D. Ramsey, MD, PhD, Director, Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA. He presented the results of a recent analysis at ASCO 2018.
Two new clinical trials with overall survival (OS) as the primary end point establish pembrolizumab (Keytruda) as a front-line standard of care in patients with non–small-cell lung cancer (NSCLC). The results were presented at ASCO 2018.
In the United States, black men are twice as likely to die from prostate cancer as white men, and they are often diagnosed at a younger age and at later stages of the disease. The reasons for these discrepancies are unclear, but the resounding message from 2 new studies presented at ASCO 2018 is that when American black men have access to good care, their response to treatment and their survival rates are at least as good as, and possibly better than, those for American white men.
Tumors with high microsatellite instability (MSI-H) are predictive of Lynch syndrome. The recent approval of the first immunotherapies for use in patients with MSI-H or with mismatch repair-deficiency (dMMR) in solid tumors is now leading to routine testing for MSI-H or dMMR in patients with advanced solid tumors.
Genomic testing is now standard of care for patients with non–small-cell lung cancer (NSCLC). The 4 identified genomic mutations that are targetable with FDA-approved therapies include EGFR, ALK, ROS1, and BRAF, and other NSCLC-associated genetic mutations are targetable with therapies currently being investigated in clinical trials. More genetic mutations are linked to NSCLC, but there is currently no accepted standard for genomic testing in NSCLC, or the optimal timing of such tests.
Poly (ADP ribose) polymerase (PARP) inhibitors are among the new and improved classes of cancer drugs, but their steep costs have become a critical consideration for patients and clinicians. The results of a recent analysis suggest that PARP inhibitors may be the least cost-effective of available maintenance therapies for advanced ovarian cancer. According to data presented at ASCO 2018, to become cost-neutral with anti-VEGF therapy, PARP inhibitors would require at least a 50% reduction in cost.
Healthcare costs in the United States have spiraled out of control, and polls show that single-payer healthcare is gaining traction. Our Canadian neighbors have had a single-payer system for a long time. A study presented at ASCO 2018 puts exact numbers on what it costs to receive treatment for metastatic colorectal cancer (CRC) in demographically similar populations in Washington State versus British Columbia, geographic areas separated by a line of sand but vastly different in terms of "bang for the buck" in cancer care.
With healthcare premiums on the rise and out-of-pocket costs skyrocketing, almost every person diagnosed with cancer is at risk for being underinsured, but this threat extends beyond a patient's bank balance. Recent research has shown that when patients face extreme financial distress, they have a greater risk for worse outcomes, including mortality. At ASCO 2018, Yousuf Zafar, MD, MHS, Director, Center for Applied Cancer Health Policy, Duke Cancer Institute, Durham, NC, discussed the need to prevent financial toxicity at the patient level by focusing on high-­value interventions.
Page 2 of 3
Results 11 - 20 of 24
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME